Latest news with #GANX
Business Insider
29-05-2025
- Business
- Business Insider
Gain Therapeutics files $100M mixed securities shelf
17:02 EDT Gain Therapeutics (GANX) files $100M mixed securities shelf Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
17-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Reviva Pharmaceuticals Holdings (RVPH)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gain Therapeutics (GANX – Research Report) and Reviva Pharmaceuticals Holdings (RVPH – Research Report) with bullish sentiments. Confident Investing Starts Here: Gain Therapeutics (GANX) BTIG analyst Thomas Shrader maintained a Buy rating on Gain Therapeutics on May 15 and set a price target of $10.00. The company's shares closed last Friday at $2.01. According to Shrader is a 1-star analyst with an average return of -1.0% and a 33.4% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and Arcturus Therapeutics. Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.00, which is a 337.2% upside from current levels. In a report issued on April 30, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target. Maxim Group analyst Jason McCarthy maintained a Buy rating on Reviva Pharmaceuticals Holdings yesterday and set a price target of $5.00. The company's shares closed last Friday at $0.82, close to its 52-week low of $0.60. According to McCarthy has 0 stars on 0-5 stars ranking scale with an average return of -21.7% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, SELLAS Life Sciences Group, and Actinium Pharmaceuticals. Currently, the analyst consensus on Reviva Pharmaceuticals Holdings is a Strong Buy with an average price target of $11.25.
